ESCONDIDO, Calif., July 9, 2020 /PRNewswire/ -- TearLab Corporation (TearLab), a leader in diagnostics for dry eye disease (DED), today announced their acquisition by Accelmed Partners II (AP-II). As a newly formed private company, TearLab is now positioned to pursue further development of its...

ESCONDIDO, Calif., May 11, 2020 -- TearLab Corporation (OTCQB: TEAR), a leader in Ocular Surface Diagnostics,  today  announced  it  has  entered  into  a  definitive  agreement  pursuant  to  which  Accelmed Partners  II  (AP-II)  will  acquire  TearLab.  In  connection  with  the  acquisition, ...

ESCONDIDO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- In light of recent market rumors, TearLab Corporation (OTCQB: TEAR) (“TearLab”) today confirmed that TearLab is engaged in advanced discussions regarding a potential business combination whereby TearLab will be acquired at a price per share equal...

ESCONDIDO, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its 510(k) application for the potential clearance of its TearLab Discovery™ MMP-9...

ESCONDIDO, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the fourth quarter and twelve months ended December 31, 2019. All dollar amounts are expressed in U.S. currency and results are...

ESCONDIDO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the third quarter ended September 30, 2019. All dollar amounts are expressed in U.S. currency and results are reported in...

ESCONDIDO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the second quarter ended June 30, 2019. All dollar amounts are expressed in U.S. currency and results are reported in accordance...

ESCONDIDO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the first quarter ended March 31, 2019. All dollar amounts are expressed in U.S. currency and results are reported in accordance...

ESCONDIDO, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the fourth quarter and twelve months ended December 31, 2018. All dollar amounts are expressed in U.S. currency and results are...

ESCONDIDO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the third quarter ended September 30, 2018. All dollar amounts are expressed in U.S. currency and results are reported in...

SAN DIEGO, Oct. 10, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has determined that the TearLab Discovery™ MMP-9 test, has not met the criteria for substantial equivalence based upon data...

SAN DIEGO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the second quarter ended June 30, 2018. All dollar amounts are expressed in U.S. currency and results are reported in accordance with...

SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the first quarter ended March 31, 2018. All dollar amounts are expressed in U.S. currency and results are reported in accordance with...

SAN DIEGO, April 11, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (“TearLab” or the “Company”) today announced that it has received written feedback from the Food and Drug Administration (FDA) on the requirements for 510(k) clearance of its TearLab Discovery™ Platform and test card...

SAN DIEGO, March 16, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX:TLB) (“TearLab” or the “Company”) today announced that it has applied and received approval for a voluntary delisting of its common stock from the Toronto Stock Exchange (TSX) in Canada. The delisting from the TSX...

SAN DIEGO, March 02, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX:TLB) (“TearLab” or the “Company”) today reported its consolidated financial results for the fourth quarter and twelve months ended December 31, 2017. All dollar amounts are expressed in U.S. currency and results are...

Launch planned at the 2018 Simpósio Internacional Moacyr Álvaro (SIMASP) Annual Meeting Launch planned at the 2018 Simpósio Internacional Moacyr Álvaro (SIMASP) Annual

SAN DIEGO, Feb. 14, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX:TLB) (“TearLab” or the “Company”) today announced its plans to appeal a recent ruling from the Federal Court of Canada related to its single Canadian patent. TearLab initiated the lawsuit against I-Med Pharma and its...

SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX:TLB) (“TearLab” or the “Company”) today announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for the potential clearance of its TearLab Discovery™ Platform, the...

SAN DIEGO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX:TLB) (“TearLab” or the “Company”), today announced the pricing of a registered direct offering of 6,818,182 units at a purchase price of $0.44 each, raising gross proceeds of $3.0 million, prior to any placement...

SAN DIEGO, Nov. 30, 2017 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX:TLB) (“TearLab” or the “Company”), today announced that it is launching a registered direct offering to raise gross proceeds of approximately $3.0 million, prior to any placement agent commissions and other...